



DOWNSTREAM INDUSTRIAL BIOTECHNOLOGY

Recovery and Purification

MICHAEL C. FLICKINGER, EDITOR

 WILEY

Table of Contents

[Title Page](#)

[Copyright](#)

[Preface](#)

[Contributors](#)

[Part I: Introduction](#)

[Introduction](#)

[Chapter 1: Bioprocess Design, Computer-Aided](#)

[1.1 Introduction](#)

[1.2 Benefits From the Use of Computer Aids](#)

[1.3 Commercially Available Tools](#)

[1.4 Monoclonal Antibody Example](#)

[1.5 Design and Operation of Multiproduct Facilities](#)

[1.6 Summary and Conclusions](#)

[References](#)

[Part II: Downstream recovery of cells and protein capture](#)

Chapter 2: Cell Separation, Centrifugation

2.1 Introduction

2.2 Centrifugal Separation

2.3 Types of Centrifugal Separators

2.4 Fluid and Particle Dynamics

2.5 The Theoretical Size of a Centrifugal Separator

2.6 Selection of Type and Size of Centrifuge

2.7 Description of Some Applications

2.8 Installation and Operation

2.9 Centrifugation Versus Microfiltration

2.10 Nomenclature

References

Chapter 3: Cell Disruption, Micromechanical Properties

3.1 Introduction

3.2 Microorganisms: Composition and Morphology

3.3 Micromechanical Properties of Microorganisms

3.4 Cell Disruption

3.5 Comparison of Different Cell Disruption Devices

3.6 Correlation of Micromechanical Results with Cell Disruption Results

3.7 Nomenclature

3.8 Greek Letters

References

Chapter 4: Cell Separation, Yeast Flocculation

4.1 Introduction

4.2 Microbial Aggregation and Yeast Flocculation: Scope and Definitions

4.3 Genetics of Yeast Flocculation

4.4 Molecular Mechanism of Yeast Flocculation

4.5 Inductively Versus Constitutively Flocculent Strains

4.6 Environmental Factors Affecting Yeast Flocculation

4.7 Yeast Flocculation and Biotechnological Processes

4.8 Conclusions

References

Chapter 5: Cell Wall Disruption and Lysis

5.1 Introduction

5.2 The Cell Wall

5.3 Assessment of the Disruption Yield

5.4 Methods of Cell Wall Disruption

5.5 Effects of Cell Disruption on Downstream Operations

5.6 Process Intensification By Integration of Disruption with Protein Capture

References

Chapter 6: Expanded Bed Chromatography, Surface Energetics of

Biomass Deposition

6.1 Introduction

6.2 Technical Challenges in EBA

6.3 Surface Thermodynamics of Biomass
Deposition in EBA

6.4 Surface Energetics and Protein Adsorption

6.5 Conclusion

6.6 Nomenclature

References

Further Reading

Chapter 7: Filter Aids

7.1 Introduction

7.2 Process Clarification

7.3 Porous Media in Dynamic Process Filtrations

7.4 Fundamental Principles of Diatomite Filtration

7.5 Grade Selection and Optimization

7.6 Systematic Methods Development Approach
to Grade Selection

7.7 Summary

References

Chapter 8: Protein Adsorption, Expanded Bed

8.1 Introduction

8.2 Theory

8.3 Principles of Operation

8.4 Equipment

8.5 Applications

[References](#)

[Further Reading](#)

[Part III: Process Development in Downstream Purification](#)

[Chapter 9: Scaledown Of Biopharmaceutical Purification Operations](#)

[9.1 Introduction](#)

[9.2 General Considerations](#)

[9.3 Centrifugation](#)

[9.4 Homogenization](#)

[9.5 Refolding](#)

[9.6 Precipitation](#)

[9.7 Chromatography](#)

[9.8 Microfiltration And Ultrafiltration/Diafiltration
\(UF/DF\)](#)

[9.9 Viral Clearance Via Chromatography And
Filtration](#)

[9.10 Viral Inactivation](#)

[9.11 Membrane Adsorbers](#)

[9.12 Summary](#)

[9.13 List Of Abbreviations](#)

[9.14 Nomenclature](#)

[References](#)

[Chapter 10: Adsorption in Simulated Moving Beds \(SMB\)](#)

[10.1 Introduction](#)

[10.2 Fundamentals of Chromatographic Separations](#)

[10.3 Design of Operating Conditions](#)

[10.4 Applications](#)

[10.5 Advances of SMB Technology](#)

[10.6 Concluding Remarks](#)

[10.7 Nomenclature](#)

[References](#)

[Further reading](#)

[Chapter 11: Adsorption of Proteins with Synthetic Materials](#)

[11.1 Interfaces](#)

[11.2 Proteins at Interfaces](#)

[References](#)

[Chapter 12: Affinity Fusions for Protein Purification](#)

[12.1 Introduction](#)

[12.2 Systems for Rapid Protein Capture](#)

[12.3 Stabilization of Expressed Proteins](#)

[12.4 Detection of Produced Proteins](#)

[12.5 Removal of Affinity Tags](#)

[12.6 Utilization of Fusion Proteins as Antigens](#)

[12.7 Subunit Immunogens for Vaccine Research](#)

[12.8 Conclusions](#)

[References](#)

Chapter 13: Bioseparation, Magnetic Particle Adsorbents

13.1 Introduction

13.2 Selected Scalable Synthesis Procedures

13.3 Magnetic Adsorbents for Laboratory Separations

13.4 Magnetic Separation Techniques

13.5 Summary

References

Chapter 14: High Throughput Technologies in Bioprocess Development

14.1 Introduction

14.2 HTT Applied to Upstream Cell Culture Development

14.3 HTT Applied to Downstream Purification Development

14.4 Analysis Needs for High Throughput Formats

14.5 Experimental Design for HTT

14.6 Conclusion

References

Chapter 15: Large-Scale Protein Purification, Self-Cleaving Aggregation Tags

15.1 Introduction

15.2 Conventional Affinity-Tag Technology

15.3 Self-Cleaving in Proteins

[15.4 Conventional Self-Cleavable Affinity Tags](#)
[15.5 Self-Cleaving Aggregation Tags](#)
[15.6 Advantages, Economy and Future Prospects of Self-Cleaving Aggregation-Tag Technologies](#)
[References](#)

[Chapter 16: Lipopolysaccharide, LPS removal, Depyrogenation](#)

[16.1 Introduction](#)
[16.2 Endotoxins: Chemical and Physical Properties](#)
[16.3 Mechanism of Endotoxin Action](#)
[16.4 Techniques Applied for Endotoxin Removal](#)
[16.5 Endotoxin Removal in Biotechnology Manufacturing Processes](#)
[References](#)

[Chapter 17: Porous Media in Biotechnology](#)

[17.1 Introduction](#)
[17.2 General Definitions](#)
[17.3 Characteristics of Porous Media](#)
[17.4 Transport Phenomena in Porous Systems](#)
[17.5 Porous Media in Bioprocesses](#)
[17.6 Conclusion](#)
[References](#)

[Chapter 18: Protein Aggregation and Precipitation, Measurement and Control](#)

18.1 Introduction

18.2 Combining Methods to Follow Aggregation and Precipitation and Determine The Structure of Complexes

18.3 SPECTRAL METHODS FOR MEASURING SOLUBILITY AND PROTEIN ASSOCIATION

18.4 Understanding Protein-Solvent Interactions Protein Stability in A Practical Sense

18.5 DETERMINING THE SURFACE CHARGE AND HYDROPHOBICITY OF A PROTEIN

18.6 Empirical Models for Salting in and Precipitation with Various Agents

18.7 MODELS FOR DETERMINING THE EFFECT OF CO-SOLVENTS ON PROTEIN FOLDING

18.8 Computer Design of More Soluble Proteins

18.9 Automatic Homology Modeling

18.10 Modeling Using Self-Correcting Distance Geometry with The Programs CLUSTAL, MASIA, NOAH, DIAMOD, and FANTOM, to Develop A 3D Model of A Protein

18.11 Conclusions

References

Part IV: Equipment Design for Downstream Recovery and Protein Purification

Chapter 19: Cleaning and Sanitation in Downstream Processes

[19.1 Introduction](#)

[19.2 Designing an Effective Cleaning Protocol for Downstream Bioprocesses](#)

[19.3 Chromatographic Media](#)

[19.4 Cross-Flow Filtration \(CFF\)](#)

[19.5 Equipment](#)

[19.6 Sanitization and Sterilization](#)

[19.7 Cleaning Validation](#)

[19.8 Conclusions](#)

[References](#)

[Chapter 20: Clean-in-place](#)

[20.1 Introduction](#)

[20.2 The Requirement for CIP Systems](#)

[20.3 General Outline of a CIP Regime](#)

[20.4 CIP Chemicals](#)

[20.5 CIP Design and Construction](#)

[20.6 CIP Configuration](#)

[20.7 Automation](#)

[20.8 Validation and Verification](#)

[References](#)

[Further Reading](#)

[Chapter 21: Large Scale Chromatography. Columns, Modeling Flow Distribution](#)

[21.1 Introduction](#)

[21.2 Challenges of Scaling up Chromatography](#)

[21.3 Analysis on the Wall Effect](#)

[21.4 Model the Coupling Between Bed Compression and Flow](#)

[21.5 IMPACT OF HARDWARE DESIGN ON THE FLOW IN LARGE COLUMNS](#)

[21.6 Modeling the Transport of Elution and HETP Analysis](#)

[Summary](#)

[List of Abbreviations](#)

[Nomenclature](#)

[References](#)

[Chapter 22: Pumps, Industrial](#)

[22.1 Introduction](#)

[22.2 Theory](#)

[22.3 Centrifugal Pumps](#)

[22.4 Positive Displacement Pumps](#)

[22.5 Drivers](#)

[22.6 Special Considerations for Bioprocessing Pumps](#)

[22.7 Troubleshooting](#)

[Additional Reading](#)

[Part V: Downstream cGMP Operations](#)

[Chapter 23: Affinity Chromatography of Plasma Proteins](#)

[23.1 Introduction](#)

[23.2 Ligands and Supports for Affinity Purification](#)

[23.3 Application of Affinity Chromatography in Plasma Protein Processes](#)

[23.4 Quality Control of Affinity-Purified Proteins](#)

[23.5 Conclusions](#)

[References](#)

[Chapter 24: Antibody Purification, Monoclonal and Polyclonal](#)

[24.1 Introduction](#)

[24.2 Approach to Downstream Processing](#)

[24.3 Affinity Chromatography](#)

[24.4 Ion-Exchange Chromatography](#)

[24.5 Hydrophobic Interaction Chromatography](#)

[24.6 Ceramic Hydroxyapatite Chromatography](#)

[24.7 Mixed Mode Chromatography](#)

[24.8 Purification of IgM](#)

[24.9 Platform Processes](#)

[24.10 Conclusion](#)

[References](#)

[Chapter 25: Chromatographic Purification of Virus Particles](#)

[25.1 Introduction](#)

[25.2 Chromatographic Separation Methods](#)

[25.3 Adsorption Chromatography](#)

[25.4 Ion Exchange Chromatography](#)

[25.5 Hydrophobic Interactions Chromatography](#)

[25.6 Multimodal Methods](#)

[25.7 Other Multimodal Methods](#)

[25.8 Biospecific Affinity Chromatography](#)
[25.9 Process Development](#)
[25.10 Sample Definition](#)
[25.11 Sample Preparation](#)
[25.12 Initial Screening](#)
[25.13 Biospecific Affinity](#)
[25.14 Interpretation of Initial Results](#)
[25.15 Concluding Remarks](#)
[25.16 Recommended Reading](#)
[References](#)

[Chapter 26: Chromatography, Hydrophobic Interaction](#)

[26.1 Introduction](#)
[26.2 Hydrophobic Interaction](#)
[26.3 Hydrophobic Interaction Chromatography](#)
[26.4 Classifying of Media and Modelling of Chromatographic Results](#)
[26.5 The Chromatography Conditions](#)
[26.6 Regeneration and Cleaning-in-Place](#)
[26.7 Optimization Procedures](#)
[26.8 Applications](#)
[References](#)

[Chapter 27: Chromatography, Radial Flow](#)

[27.1 Introduction](#)
[27.2 Radial Flow Column Configurations](#)
[27.3 Packing Procedures for RFC Columns](#)
[27.4 Pressure Drops of RFC Columns](#)

[27.5 Comparison of Radial- and Axial Flow Columns](#)

[27.6 Pros and Cons of RFC Columns](#)

[27.7 Application Examples](#)

[27.8 Mathematical Modeling of Radial Flow Chromatography](#)

[27.9 Scale-Up of RFC Columns](#)

[27.10 Conclusions](#)

[Nomenclature](#)

[Greek Letters](#)

[References](#)

[Chapter 28: Drying, Biological Materials](#)

[28.1 Introduction](#)

[28.2 Drying of Biotechnological Products](#)

[28.3 Effect of Drying on Biotechnological Product Quality](#)

[28.4 Basic Principle of Drying](#)

[28.5 Commonly Used Dryers](#)

[28.6 Some Emerging Drying Technologies](#)

[28.7 Closing Remarks](#)

[References](#)

[Chapter 29: Freeze-Drying, Pharmaceuticals](#)

[29.1 Introduction](#)

[29.2 Pharmaceutical Freeze-Drying: Fundamentals](#)

[29.3 Challenges and New Advancements in Freeze-Drying](#)
[References](#)

[Chapter 30: Freezing, Biopharmaceutical](#)

[30.1 Introduction](#)
[30.2 Freezing of Solutions](#)
[30.3 Thawing of Solutions](#)
[30.4 Freeze-Thaw Scale Up](#)
[30.5 Conclusion](#)
[References](#)

[Chapter 31: Membrane Chromatography](#)

[31.1 Introduction](#)
[31.2 The Basic Concept](#)
[31.3 Limiting Factors in Membrane Adsorption Processes](#)
[31.4 Optimizing The Performance of Adsorptive Membranes](#)
[31.5 POSITIONING OF MEMBRANE ADSORPTION IN A PURIFICATION TRAIN](#)
[31.6 Applications](#)
[31.7 Concluding Remarks](#)
[Nomenclature](#)
[References](#)

[Chapter 32: Membrane Separations](#)

[32.1 Membrane Separations](#)
[32.2 Introduction](#)

[32.3 Three major applications of membrane separations](#)

[32.4 Classification of Membranes and Membrane Processes](#)

[32.5 Membrane Chemistry, Structure and Function](#)

[32.6 Methods of Membrane Manufacture](#)

[32.7 How Membrane Processes are Operated](#)

[32.8 Conclusion](#)

[References](#)

[Chapter 33: Plasmid Purification](#)

[33.1 Introduction](#)

[33.2 Therapeutic Plasmids](#)

[33.3 Cell Lysis](#)

[33.4 Chromatographic Methods](#)

[33.5 Nonchromatographic Methods](#)

[33.6 Industrial Processes](#)

[33.7 Conclusions and Perspectives](#)

[References](#)

[Chapter 34: Protein Chromatography, Manufacturing Scale](#)

[34.1 Introduction](#)

[34.2 Scale-Up of Chromatography](#)

[34.3 Impact of Chromatographic Parameters at Manufacturing Scale](#)

[34.4 Practical Issues Regarding Chromatography at Manufacturing Scale](#)

[34.5 Basic Chromatography Setup](#)
[References](#)

[Chapter 35: Protein Crystallization, Kinetics](#)

[35.1 Protein Molecules in Solution](#)

[35.2 Homogeneous Nucleation](#)

[35.3 Heterogeneous Nucleation](#)

[35.4 Nonclassical Approach to Nucleation](#)

[35.5 Crystal Growth](#)

[35.6 Crystallization in Forced Solution Flow Regime](#)

[References](#)

[Chapter 36: Protein Purification, Aqueous Liquid Extraction](#)

[36.1 Introduction](#)

[36.2 Biochemical Fundamentals](#)

[36.3 Alternative Two-Phase Systems](#)

[36.4 Applications](#)

[36.5 Conclusion](#)

[References](#)

[Chapter 37: Protein Ultrafiltration](#)

[37.1 Introduction](#)

[37.2 Theoretical Principles](#)

[37.3 Membrane Materials, Characterization, and Fouling](#)

[37.4 Modules and Devices](#)

[37.5 Equipment](#)
[37.6 Process Configurations](#)
[37.7 Process Design—Ultrafiltration](#)
[37.8 High Performance Tangential Flow Filtration](#)
[37.9 Scale-Up](#)
[Nomenclature](#)
[References](#)

[Chapter 38: Virus Retentive Filters](#)

[38.1 Process Virology Overview](#)
[38.2 Principles of Operation](#)
[38.3 Physical Attributes](#)
[38.4 Process Considerations](#)
[38.5 Filtration Modes](#)
[38.6 Filter Classes](#)
[38.7 Integrity Testing](#)
[38.8 Performance](#)
[38.9 Validation \(Virus Clearance Evaluation\) Studies](#)
[38.10 Future Trends](#)
[38.11 Concluding Comments](#)
[List of Abbreviations](#)
[References](#)

[Part VI: Biopharmaceutical Facility Validation](#)

[Chapter 39: Biopharmaceutical Facility Design and Validation](#)

[39.1 Introduction](#)
[39.2 Designing for Compliance](#)
[39.3 Risk Management](#)
[39.4 Qualification/Verification](#)
[39.5 Process Validation](#)
[List of Abbreviations](#)
[References](#)

[Chapter 40: Closed Systems in Bioprocessing](#)

[40.1 Introduction](#)
[40.2 Definition of Closed Systems](#)
[40.3 Closed System Design](#)
[40.4 Impact on Facility Design](#)
[40.5 Impact on Operations](#)
[40.6 Summary](#)
[References](#)

[Chapter 41: Facility Design for Single Use \(SU\) Downstream Materials](#)

[41.1 Introduction](#)
[41.2 Facility Design](#)
[41.3 Cell Culture](#)
[41.4 Purification](#)
[41.5 Applications in A Fill and Finish Plant](#)
[41.6 Media Buffer](#)
[41.7 Costs](#)
[41.8 Conclusions](#)
[References](#)

Chapter 42: Cgmps For Production Rooms

42.1 General Points for Facility Design

42.2 Design of HVAC System Parameters

References

Additional Reading

Chapter 43: Heating, Ventilation, and Air Conditioning

43.1 Introduction

43.2 HVAC Design Process

43.3 Regulation and Code Consideration

43.4 Temperature, Humidity, and Airflow

43.5 Pressurization

43.6 Air Handling Systems

43.7 Dehumidifiers

43.8 Humidifiers

43.9 Air Handling Unit Application

43.10 Return and Exhaust Fan Selection and Locations

43.11 HEPA Filters

43.12 Terminal Air Control Devices

43.13 Air Terminal Outlets

43.14 Duct Materials, Pressure, and Cleanability

43.15 System Operating Procedures

43.16 Emergency Electrical Power

43.17 Building Control and Automation Systems

43.18 Testing, Balancing, and Cleaning

43.19 Validation

43.20 Summary

References

Chapter 44: Sterilization-in-Place (SIP)

44.1 Introduction

44.2 Applications

44.3 Steam-in-Place Technology

44.4 Alternative SIP Technologies

References

Part VII: FDA cGMP Regulatory Compliance

Chapter 45: Pharmaceutical Bioburden Testing

45.1 Introduction

45.2 Bioburden Considerations

45.3 Standard Industry Methodologies

45.4 New and Rapid Technologies

45.5 Conclusion

References

Further Reading

Chapter 46: Chromatography, Industrial Scale Validation

46.1 Introduction

46.2 Systems Requirements

46.3 CFR Part 11 Software Evaluation Checklist for Closed Systems which do not use Biometrics

[46.4 Gmp Requirements](#)

[46.5 Conclusion](#)

[Chapter 47: GMPs and GLSPs](#)

[47.1 Introduction](#)

[47.2 Facility Regulatory Guidelines](#)

[47.3 Major Focuses of Facility Performance](#)

[Validation](#)

[47.4 Investigations Of Nonconformances And](#)

[Deviations](#)

[Chapter 48: Quality by Design \(QBD\)](#)

[48.1 Biopharmaceutical Development](#)

[48.2 Key Steps for Implementing QbD](#)

[48.3 Quality Risk Management for](#)

[Biopharmaceuticals](#)

[48.4 Design Space\(S\) for Biopharmaceuticals](#)

[48.5 PAT in Biopharmaceutical Manufacture](#)

[48.6 Hypothetical QbD Case Study for a](#)

[Biopharmaceutical: Anion Exchange](#)

[Chromatography](#)

[48.7 FDA's QbD Pilot Program for](#)

[Biopharmaceuticals](#)

[48.8 Summary](#)

[48.9 List of Abbreviations](#)

[Chapter 49: Regulatory Requirements, European Community](#)

[49.1 The European Union](#)

[49.2 The European Medicines Agency \(EMA\)](#)
[49.3 New Drug Approval Routes Coordinated by the Ema](#)
[49.4 The Ema in the Context of Drug Development and Manufacture](#)
[49.5 Concluding Remarks](#)
[References](#)

[Index](#)

DOWNSTREAM INDUSTRIAL BIOTECHNOLOGY

Recovery and Purification

Edited By

MICHAEL C. FLICKINGER

Golden LEAF Biomanufacturing Training and Education Center (BTEC)
Department of Chemical and Biomolecular Engineering
North Carolina State University, Raleigh
North Carolina, USA



A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2013 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey

Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care

Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data:

Encyclopedia of industrial biotechnology. Selections.

Downstream industrial biotechnology : recovery and purification / edited by Michael C. Flickinger.

pages cm

Includes bibliographical references and index.

ISBN 978-1-118-13124-4 (hardback)

1. Biotechnology-Encyclopedias. I. Flickinger, Michael C., editor of compilation. II. Title.

TP248.16.E533 2013

660.6--dc23

2012030526

Preface

Downstream Industrial Biotechnology is a compilation of essential in depth articles, organized topically and listed in alphabetical format, for biopharmaceutical, bioprocess and biologics process scientists, engineers and regulatory professionals from the comprehensive seven volumes of the *Encyclopedia of Industrial Biotechnology*. Process development for the manufacture of complex biomolecules involves solving many scientific, compliance and technical problems quickly in order to support pilot, preclinical and clinical development, technology transfer and manufacturing start-up. Every organization develops new processes from accumulated process knowledge. Accumulated process knowledge has a very significant impact on accelerating the time to market (and reducing the financial resources required) of products manufactured using recombinant DNA and living microbes, cells, transgenic plants or transgenic mammals. However, when an entirely new upstream platform or downstream unit operation is needed, there are few books that will quickly provide the depth of industry-relevant background. *Downstream Industrial Biotechnology* can fill this void as an advanced desk reference. This volume includes relevant biology, protein purification and engineering literature with abundant process examples provide by industry subject matter experts (SMEs) and academic scholars. This desk reference will also be useful for advanced biomanufacturing students and professionals to quickly gain in depth knowledge on how to design processes (and facilities) capable of being licensed to manufacture enzymes, biopharmaceutical intermediates, human and veterinary biopharmaceuticals or vaccines. The opportunity is yours to leverage the combined knowledge from scores of industry

professionals from around the world who have contributed to *Downstream Industrial Biotechnology* to reduce the time and cost to deliver engineered proteins, biomolecules and cost-effective biologics to the market and especially to millions of patients worldwide.

Professor Michael C. Flickinger, Editor

Golden LEAF Biomanufacturing Training and Education Center (BTEC)

Department of Chemical and Biomolecular Engineering

North Carolina State University

Raleigh, North Carolina, 27695-7928, USA

Contributors

Muhammad Aasim Downstream Bioprocessing Laboratory, School of Engineering and Science, Jacobs University, Bremen, Germany

Oscar Aguilar Centro de Biotechnologia Tecnolico de Monterrey, Monterrey, Mexico

Mattias Ahnfelt GE Healthcare Bio-Sciences AB, Uppsala, Sweden

Hazel Aranha GAEA Resources Inc., Northport, New York, USA

Claude Artois University of Surrey, Guildford, Surrey, United Kingdom; SmithKline Beecham Biologicals, Rixensart, Belgium

Hans Axelsson Alfa Laval AB, Tumba, Sweden

Diana C.S. Azevedo Federal University of Ceara, Fortaleza-CE, Brazil

H.S.C. Barbosa Center of Chemistry, University of Minho, Campus de Gualtar, Braga, Portugal

Sonja Berensmeier Technische Universitat Munchen, Institute of Biochemical Engineering, Garching, Germany

Joseph Bertolini CSL Bioplasma, Broadmeadows, Victoria, Australia

Darcy Birse Fast Trak Biopharma Services, GE Healthcare, Piscataway, New Jersey, USA

Eggert Brekkan GE Healthcare Bio-Sciences AB, Uppsala, Sweden

Phil J. Bremer University of Otago, Dunedin, New Zealand

Kurt Brorson Office of Biotech Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA